Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
BIDINOTTO, Lucas Tadeu
VEO, Carlos A. R.
LOAIZA, Edgar Aleman
FRANCA, Alessandra Paulino Santos De
LORENZI, Adriana Tarla
SCAPULATEMPO-NETO, Cristovam
LONGATTO-FILHO, Adhemar
Citação
MOLECULAR MEDICINE REPORTS, v.14, n.4, p.3791-3797, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Anal cancer is a rare type of digestive tract disease, which has had a crescent incidence in a number of regions. Carcinomas are most frequently found, with squamous cell carcinoma (SCC) comprising similar to 95% of all anal tumors. The major risk factor for development of this type of tumor is human papillomavirus (HPV) infection. However, previous studies have identified patients with anal cancer that are HPV-/p16-and observed that they have a poorer outcome compared with HPV+/p16+ patients. This suggests that molecular profile may drive anal cancer progression. The aim of the present study was to evaluate the mutational status of two important oncogenes, KRAS and BRAF, in a series of anal cancer lesions. Resected tumors of the anal canal (n=43) were evaluated, nine of these were high-grade squamous intra-epithelial lesion cases (HSIL), 11 were adenocarcinomas, and 23 SCCs. Direct sequencing of KRAS proto-oncogene, GTPase (KRAS; codons 12 and 13) and B-Raf proto-oncogene, serine/threonine kinase (BRAF; codon 600) was performed and associated with patient clinicopathological and molecular features. There was a trend of poorer prognosis of adenocarcinoma compared with HSIL and SCC. Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation. It was observed that, these mutations are rare in anal tumors, and certain patients may be at a disadvantage using targeted therapies based on KRAS and BRAF mutational status. As there is a low mutation percentage in SCCs, adenocarcinomas and HSIL, there may exist other underlying molecular alterations that result in anal cancer development, which require further elucidation.
Palavras-chave
anal cancer, squamous cell carcinoma, adenocarcinoma, high-grade squamous intra-epithelial lesion, KRAS, BRAF
URI
https://observatorio.fm.usp.br/handle/OPI/17253
Referências
  1. Bartelink H, 1997, J CLIN ONCOL, V15, P2040
  2. Bosman FT, 2010, WHO CLASSIFICATION T
  3. Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
  4. De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
  5. DEANS GT, 1994, BRIT J SURG, V81, P500, DOI 10.1002/bjs.1800810405
  6. Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
  7. El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356
  8. Ferreira CG, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-73
  9. Franceschi S, 2009, CURR OPIN HIV AIDS, V4, P57, DOI 10.1097/COH.0b013e32831b9c81
  10. Franklin RA, 2016, CLIN COLORECTAL CANC, V15, P47, DOI 10.1016/j.clcc.2015.07.007
  11. Gardini AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092071
  12. Gilbert DC, 2013, RADIOTHER ONCOL, V109, P146, DOI 10.1016/j.radonc.2013.08.002
  13. Lampejo T, 2010, BRIT J CANCER, V103, P1858, DOI 10.1038/sj.bjc.6605984
  14. Leonard Daniel, 2011, Clin Colon Rectal Surg, V24, P54, DOI 10.1055/s-0031-1272824
  15. Lukan N, 2009, ONCOLOGY-BASEL, V77, P293, DOI 10.1159/000259615
  16. Mai S, 2015, INT J RADIAT ONCOL, V93, P819, DOI 10.1016/j.ijrobp.2015.08.004
  17. Martin V, 2014, HISTOL HISTOPATHOL, V29, P513
  18. Matalon SA, 2015, RADIOGRAPHICS, V35, P2091, DOI 10.1148/rg.2015150037
  19. Meulendijks D, 2015, BRIT J CANCER, V112, P1358, DOI 10.1038/bjc.2015.20
  20. Okumura S, 2014, CLIN CANCER RES, V20, P4193, DOI 10.1158/1078-0432.CCR-13-2365
  21. Paliga A, 2012, BRIT J CANCER, V107, P1864, DOI 10.1038/bjc.2012.479
  22. Prigge ES, 2014, HUM PATHOL, V45, P2347, DOI 10.1016/j.humpath.2014.08.001
  23. Rousseau DL, 2005, SURG ONCOL, V14, P121, DOI 10.1016/j.suronc.2005.07.002
  24. Scapulatempo-Neto C, 2016, ONCOL LETT
  25. Serup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464
  26. Serup-Hansen E, 2015, APMIS, V123, P53, DOI 10.1111/apm.12306
  27. Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
  28. Smaglo BG, 2015, ONCOTARGET, V6, P43594, DOI 10.18632/oncotarget.6202
  29. Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
  30. Veo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
  31. Yamane LS, 2014, ONCOL REP, V32, P1419, DOI 10.3892/or.2014.3338

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03